ConductScience.org, home

Paper28075166

The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.

Chen X and 9 others. Future Oncol, 2017. Cited by 100 papers, by iCite.

Cite this record

ConductScience Library. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis. Papers, record 28075166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28075166

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.
PubMed
Journal
Future Oncol
PubMed
Year
2017
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
100
iCite
Relative citation ratio, by iCite
3.43
iCite
Revised in PubMed
2025-06-23
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen XXianyu
2He CChao
3Han DDongdong
4Zhou MMeirong
5Wang QQuan
6Tian JJinhui
7Li LLun
8Xu FFeng
9Zhou EEnxiang
10Yang KKehu

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Biomarkers, TumorMajor topic
Breast NeoplasmsMajor topic
Ki-67 AntigenMajor topic
Antineoplastic Combined Chemotherapy Protocols
Female
Humans
Neoadjuvant Therapy
Odds Ratio
Prognosis
Publication Bias
Treatment Outcome

Source PubMed

Download CSV of topics

Cited by80

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 100 citations.

PMIDTitleJournalYearIn PapersSource
42801232Investigation of the Residual Tumor Burden and Prognosis of Breast Cancer.Breast Cancer (Dove Med Press)2026https://conductscience.org/library/papers/42801232PubMed
42741650Development and evaluation of clinical models based on ultrasound, serum CA153 and molecular subtype in predicting the efficacy of neoadjuvant chemotherapy in breast cancer.Oncol Lett2026https://conductscience.org/library/papers/42741650PubMed
42279314Evaluating the Association of Ki-67 with Oncotype DX Recurrence Score in Early-Stage ER-Positive/HER2-Negative Breast Cancer.Cancers (Basel)2026https://conductscience.org/library/papers/42279314PubMed
42157210A nomogram integrating p53 and Ki-67 expression for predicting recurrence risk in postoperative early gastric cancer.World J Surg Oncol2026https://conductscience.org/library/papers/42157210PubMed
41620483Evaluating the prognostic significance of HIST1H4C in breast cancer: implications for neoadjuvant therapy.Sci Rep2026https://conductscience.org/library/papers/41620483PubMed
41411609Imaging- and Tumor Biomarker-Based Multivariable Model for Early Prediction of Pathologic Complete Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.JCO Precis Oncol2025https://conductscience.org/library/papers/41411609PubMed
41368527Defining the optimal Ki67 cutoff values for survival prediction in neoadjuvant chemotherapy-treated patients with breast cancer.Front Surg2025https://conductscience.org/library/papers/41368527PubMed
41224966Temporality of change in Ki67 labelling following neoadjuvant systemic chemotherapy of breast cancer-the common drop often subsides with time.Virchows Arch2026https://conductscience.org/library/papers/41224966PubMed
41182476Ki-67 expression stratifies PD-L1-high NSCLC for immune checkpoint inhibitor plus chemotherapy: a real-world biomarker validation.Cancer Immunol Immunother2025https://conductscience.org/library/papers/41182476PubMed
40824193Predictive value of shear wave elastography and molecular subtypes for postoperative efficacy in patients with early breast cancer.Ann Med2025https://conductscience.org/library/papers/40824193PubMed
40718834The impact of circWWC3 on neoadjuvant therapy for triple-negative breast cancer and the construction of a nomogram for predicting pathological complete response after neoadjuvant therapy.Front Oncol2025https://conductscience.org/library/papers/40718834PubMed
40667551Machine learning-based prediction of disease-free survival in breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy: a retrospective multicenter cohort study.Am J Cancer Res2025https://conductscience.org/library/papers/40667551PubMed
40583394Optimizing neoadjuvant treatment in HER2-positive breast cancer: the role of HER2, HR, PD-L1 expression and regimen selection.Future Oncol2025https://conductscience.org/library/papers/40583394PubMed
40437449Ki-67-Playing a key role in breast cancer but difficult to apply precisely in the real world.BMC Cancer2025https://conductscience.org/library/papers/40437449PubMed
40201702Proliferative Markers in Breast Cancer and Chemotherapy Implications: A Comprehensive Review.Health Sci Rep2025https://conductscience.org/library/papers/40201702PubMed
40176396Clinicopathological Factors That Predict Different Responses of Breast and Axillary Tumors to Neoadjuvant Chemotherapy and Prognosis Among Patients With Node-Positive Breast Cancer: Real World Data.Thorac Cancer2025https://conductscience.org/library/papers/40176396PubMed
39799529The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.Breast Cancer Res Treat2025https://conductscience.org/library/papers/39799529PubMed
39773380The value of multiparametric MRI radiomics and machine learning in predicting preoperative Ki-67 expression level in breast cancer.BMC Med Imaging2025https://conductscience.org/library/papers/39773380PubMed
39736579Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA.BMC Womens Health2024https://conductscience.org/library/papers/39736579PubMed
39734711Predictive factors for complete pathologic response in luminal breast cancer: impact of ki67 and HER2 low expression.Ther Adv Med Oncol2024https://conductscience.org/library/papers/39734711PubMed

See all 80 cited byDownload CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ERBB22064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
MKI674288PubTator's text mininghttps://conductscience.org/library/genes/4288NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/28075166

GET https://conductscience.org/api/papers/v1/28075166/cited_by?page=2